retatrutide type 2 diabetes trial results 2024 2025 Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase clinical Retatrutide Results: 28.3% Weight Loss

S.et al (2016)

GLP-1 Coverage Cost-benefit Analysis Over the past several years, glucagon-like peptide-1 (GLP-1) medicationssuch as Wegovy and Zepboundhave reshaped metabolic care

basert p 2-rs data i en populasjon med overvekt/fedme uten diabetes type 2 (10) og 2.1-rs (14) og 3.8-rs (13) data fra pasienter med diabetes type 2

Description Retatrutide is a next-generation triple agonist peptide that acts on the GLP-1, GIP, and glucagon receptors

Weekly injections GLP-1 weight loss medications area self-administered weight loss injections that you can do yourself at home once a week (semaglutide is daily)

The starting dose of 4 units (approximately 0.20 mg) sits below the typical 0.25 mg starting point, which may help patients who are particularly sensitive to GLP-1 side effects